


Health Bulletin

Finding Relief For A Chronic, Painful Condition

(NAPSA)—Up to 20 million Americans live with the symptoms of Irritable Bowel Syndrome with Constipation (IBS-C), a debilitating, chronic digestive disorder that is two times more prevalent in women as compared to men. Many with the condition try to control their symptoms with lifestyle changes or over-the-counter medications. If these tactics are unsuccessful, female patients can speak with their healthcare providers about a prescription treatment option with an active ingredient that has been used to treat Chronic Idiopathic Constipation in adults since 2006 and has been approved to treat IBS-C in women 18 years and older.

People living with IBS-C experience symptoms of abdominal pain, discomfort and bloating associated with hard or lumpy stools. The symptoms must last for three months or more over the course of one year in order for a diagnosis of IBS-C to be made. IBS-C is present in about one-third of all IBS cases. Although people with IBS-C report many of the symptoms associated with chronic constipation, the symptom of abdominal pain differentiates IBS-C from chronic constipation. If it is not adequately treated, the severity of IBS-C symptoms can range from a mild inconvenience to severe debilitation.

The U.S. Food and Drug Administration approved AMITIZA® (lubiprostone) 8mcg capsules for the treatment of IBS-C in women



Adult women with IBS-C may find global symptom relief with AMITIZA (8mcg), approved for treatment of IBS-C.

18 years and older. AMITIZA is the only widely available FDA-approved prescription treatment option that can provide overall symptom relief for the millions of adult women in the U.S. with IBS-C.

“IBS-C is a multi-symptom disorder and is one of the most common conditions seen by gastroenterologists,” said Charles Baum, M.D., executive medical director, Gastroenterology and Internal Medicine, Takeda Pharmaceuticals North America, Inc. “AMITIZA makes it possible for appropriate patients to receive a widely available FDA-approved treatment for their IBS-C.”

AMITIZA is developed by Sucampo Pharmaceuticals, Inc. and marketed in the U.S. in partnership with Takeda Pharmaceuticals North America, Inc. To learn more, speak with your healthcare provider. For Full Prescribing Information, visit www.amitiza.com.



Note to Editors: About AMITIZA® (lubiprostone) for Chronic Idiopathic Constipation and IBS-C Indication

AMITIZA is approved to treat Chronic Idiopathic Constipation in adults, including those over 65 years. “Idiopathic” means the cause of the constipation is unknown and not due to an underlying illness or medication. AMITIZA is approved to treat Irritable Bowel Syndrome with Constipation (IBS-C) in women 18 years of age and older.

Important Safety Information

AMITIZA is not for everyone. If you know or suspect you have a bowel obstruction, do not take AMITIZA. If you are unsure, your doctor should evaluate your condition before starting AMITIZA. You should not take AMITIZA if you have severe diarrhea.

AMITIZA has not been studied in pregnant women and should only be used during a pregnancy if the potential benefits justify the potential risk to the fetus. Women should have a negative pregnancy test before beginning treatment with AMITIZA and need to practice effective birth control measures. If you are pregnant or become pregnant while being treated with AMITIZA, talk to your doctor to evaluate the risks.

Within an hour of taking AMITIZA, shortness of breath may occur. This symptom usually goes away within three hours, but may recur with repeated use. Tell your doctor if you have shortness of breath.

The most common side effects of taking AMITIZA (24mcg) orange capsules for Chronic Idiopathic Constipation are nausea, diarrhea, and headache. The most common side effects of taking AMITIZA (8mcg) pink capsules for IBS-C are nausea, diarrhea, and abdominal pain. If nausea occurs, take AMITIZA with food. If your diarrhea or nausea becomes severe, tell your doctor. These are not all the side effects associated with AMITIZA.

For complete Prescribing Information, please visit www.amitiza.com

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call (800) FDA-1088.